Clinical Trials
6
Active:1
Completed:5
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
CARE Initiative: Real-world Emulation of the PALOMA-2 Trial
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-09-23
- Lead Sponsor
- Aetion, Inc.
- Target Recruit Count
- 724
- Registration Number
- NCT06607601
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]
Completed
- Conditions
- Metastatic Nonsmall Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-09-23
- Lead Sponsor
- Aetion, Inc.
- Target Recruit Count
- 851
- Registration Number
- NCT06607393
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]
Completed
- Conditions
- Metastatic Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2024-09-05
- Lead Sponsor
- Aetion, Inc.
- Target Recruit Count
- 304
- Registration Number
- NCT06585189
Emulation of the KEYNOTE-189 Trial Using Electronic Health Records
Completed
- Conditions
- Non-small Cell Lung CancerMetastatic Lung Cancer
- Interventions
- Drug: Pemetrexed-Platinum
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Aetion, Inc.
- Target Recruit Count
- 1854
- Registration Number
- NCT05908799
- Locations
- 🇺🇸
Aetion, Boston, Massachusetts, United States
Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments
Active, not recruiting
- Conditions
- COVID-19
- Interventions
- Drug: Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI)
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Aetion, Inc.
- Target Recruit Count
- 3000
- Registration Number
- NCT05638932
- Locations
- 🇺🇸
Aetion, Inc., New York, New York, United States
- Prev
- 1
- 2
- Next
News
No news found